Key result
Triple antiplatelet therapy linked to better post-reperfusion stroke recovery than DAPT but increases bleeding risk.
Why the study?
Although reperfusion therapy enhances patient outcomes in ischemic stroke, the ideal antiplatelet regimen following treatment remains unclear.
Does triple antiplatelet therapy improve neurological recovery compared to dual antiplatelet therapy in ischemic stroke patients after reperfusion?
Observational (n=730)
No
Does triple antiplatelet therapy improve neurological recovery compared to dual antiplatelet therapy in ischemic stroke patients after reperfusion?
In patients with ischemic stroke post-reperfusion, triple antiplatelet therapy may improve neurological recovery at the cost of increased bleeding risk compared to dual antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Should not yet change practice post-reperfusion; hypothesis-generating for triple antiplatelet therapy in randomized trials.
BACKGROUND: Ischemic stroke is a major cause of morbidity and mortality worldwide. Although reperfusion therapy enhances patient outcomes, the ideal antiplatelet regimen post-treatment remains unclear. This study investigates the efficacy and safety of dual antiplatelet therapy (DAPT) versus triple antiplatelet therapy (TAT) in ischemic stroke patients after reperfusion. RESEARCH DESIGN AND METHODS: A retrospective observational analysis was conducted on 730 patients treated at a single institution from January 2018 to December 2023. Patients were divided into two groups: DAPT (aspirin and clopidogrel) or TAT (aspirin, clopidogrel, and tirofiban). Outcomes included neurological improvement via NIHSS scores, functional recovery using mRS, and bleeding complications. CONCLUSION: TAT may enhance neurological recovery but increases bleeding risk. Patient selection and monitoring are crucial, and long-term studies are needed to fully evaluate its risk-benefit profile.
No takes yet. Share an insight, caveat, or question.
Ju et al. (2025) conducted an observational in Ischemic stroke (n=730). Triple antiplatelet therapy (aspirin, clopidogrel, and tirofiban) vs. Dual antiplatelet therapy (aspirin and clopidogrel) was evaluated on Neurological improvement via NIHSS scores, functional recovery using mRS, and bleeding complications (p== 0.02). Triple antiplatelet therapy may enhance neurological recovery compared to dual antiplatelet therapy in ischemic stroke patients after reperfusion, but increases bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: